Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema, ...
Scientific posters will be displayed in the Experience Hub on Thursday, July 16 with the Welcome Reception. Presenters are expected to be present with their poster to discuss their research and ...
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple ...
BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase ...
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster ...
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation ...
Breadth of Data Demonstrates Growing Real-World Adoption and Clinical Importance of CareDx Testing Solutions in Heart and Lung Transplant Patient Management New SHORE Study Findings Demonstrate that ...
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the presentation of multiple clinical and scientific abstracts ...
Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that nine ...
Please Note: The submission website supports the latest version of Chrome, the current and previous release of Firefox, Safari and Microsoft browsers. Cookies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results